C77.8, Secondary and unspecified malignant neoplasm of lymph nodes of multiple regionsICD-10-CM
No Prior Auth Required
Covered without prior authorization (high confidence)
CGS-J15-L36021, MolDX: Molecular Diagnostic Tests (MDT)
J15
CGS-J15-L38584, MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells
J15
CGS-J15-L34037, Flow Cytometry
J15
CGS-J15-L35442, MolDX: NRAS Genetic Testing
J15
CGS-J15-L40386, Erythropoiesis Stimulating Agents (ESA)
J15
CGS-J15-L34356, Erythropoiesis Stimulating Agents (ESA)
J15
CGS-J18-L36021, MolDX: Molecular Diagnostic Tests (MDT)
J18
CGS-J18-L38584, MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells
J18
CGS-J18-L35442, MolDX: NRAS Genetic Testing
J18
CGS-J18-L34356, Erythropoiesis Stimulating Agents (ESA)
J18
CGS-J18-L34037, Flow Cytometry
J18
CGS-J18-L40386, Erythropoiesis Stimulating Agents (ESA)
J18
A58205, Billing and Coding: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells
J5
WPS-J5-L36797, MolDX: NRAS Genetic Testing
J5
A55147, Billing and Coding: MolDX: bioTheranostics Cancer TYPE ID Update
J5
WPS-J5-L36807, MolDX: Molecular Diagnostic Tests (MDT)
J5
A55162, Billing and Coding: MolDX: FDA-Approved KRAS Tests
J5
WPS-J5-L38678, MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells
J5
A57581, Billing and Coding: MolDX: NRAS Genetic Testing
J5
NGS-J6-L33394, Drugs and Biologicals, Coverage of, for Label and Off-Label Uses
J6
Ask Backwork about documentation requirements, denial risks, or coverage in your state.